{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:42:29Z","timestamp":1782387749066,"version":"3.54.5"},"reference-count":22,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype. This case may serve as a paradigmatic example of clonal hematopoietic progression in a patient undergoing CAR-T cell therapy, especially in the context of a TP53-mutated clone.<\/jats:p>","DOI":"10.3390\/curroncol30010087","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T03:28:10Z","timestamp":1673580490000},"page":"1146-1150","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy"],"prefix":"10.3390","volume":"30","author":[{"given":"Lea Naomi","family":"Eder","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, University Medicine Goettingen, 37075 G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2419-8416","authenticated-orcid":false,"given":"Danilo","family":"Martinovic","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, University Medicine Goettingen, 37075 G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6317-0216","authenticated-orcid":false,"given":"Paolo","family":"Mazzeo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, University Medicine Goettingen, 37075 G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ganster","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, University Medicine Goettingen, 37075 G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hasenkamp","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, University Medicine Goettingen, 37075 G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Thomson","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, University Medicine Goettingen, 37075 G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-2948","authenticated-orcid":false,"given":"Arne","family":"Trummer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, St\u00e4dtisches Klinikum Braunschweig, 38114 Braunschweig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Haase","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, University Medicine Goettingen, 37075 G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Wulf","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, University Medicine Goettingen, 37075 G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jtct.2020.10.002","article-title":"Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies","volume":"27","author":"Chakraborty","year":"2020","journal-title":"Transpl. Cell. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"101287","DOI":"10.1016\/j.beha.2021.101287","article-title":"Toxicities associated with adoptive cellular therapies","volume":"34","author":"Hansen","year":"2021","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sharma, N., Reagan, P.M., and Liesveld, J.L. (2022). Cytopenia after CAR-T Cell Therapy\u2014A Brief Review of a Complex Problem. Cancers, 14.","DOI":"10.3390\/cancers14061501"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jha2.350","article-title":"CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopenias","volume":"3","author":"Taneja","year":"2021","journal-title":"Ejhaem"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","article-title":"Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy","volume":"5","author":"Miller","year":"2021","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/2643-3230.BCD-21-0177","article-title":"Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma","volume":"3","author":"Saini","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/bloodadvances.2021005747","article-title":"Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment","volume":"6","author":"Teipel","year":"2022","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1158\/2643-3230.BCD-22-0067","article-title":"CAR T-cell Therapy Meets Clonal Hematopoiesis","volume":"3","author":"Uslu","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"E152","DOI":"10.1002\/ajh.25089","article-title":"Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes","volume":"93","author":"Martin","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","volume":"106","author":"Strati","year":"2020","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells","volume":"26","author":"Cordeiro","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11565","DOI":"10.1158\/0008-5472.CAN-06-2540","article-title":"Tumor Necrosis Factor-\u03b1 Is a Potent Endogenous Mutagen that Promotes Cellular Transformation","volume":"66","author":"Yan","year":"2006","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3324\/haematol.2019.233320","article-title":"Myelodysplastic syndrome patient-derived xenografts: From no options to many","volume":"105","author":"Balhuizen","year":"2020","journal-title":"Haematologica"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/1\/87\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:04:59Z","timestamp":1760119499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/1\/87"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["curroncol30010087"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30010087","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}